The Role of Nutraceutical Supplements in the Treatment of Irritable Bowel Syndrome: A Mini Review


Цитировать

Полный текст

Аннотация

Background:Irritable bowel syndrome (IBS) is a prolonged bowel illness that is general-ly stress-related and is characterized by a variety of gastrointestinal problems, the most prominent of which is chronic visceral abdominal discomfort. As a result, IBS typically impacts sufferers' standard of living, and it is typically associated with depression and anxiety symptoms. IBS medica-tion is based mostly on symptom alleviation. However, no effective medicines have been discov-ered too far. As a result, it is essential to discover novel anti-IBS medications.

Objective:The purpose of this brief review is to describe the existing research on nutraceutical sup-plements in irritable bowel syndrome management, including probiotics, prebiotics, symbiotics, herbal products, and dietary fibers.

Methods:This review covered the relevant papers from the previous twenty years that were availa-ble in different journals such as Science Direct, Elsevier, NCBI, and Web of Science that were re-lated to the role and function of Nutraceuticals in Irritable Bowel Syndrome.

Results:Neutraceutical substances have a variety of modes of action, including restoring the healthy microbiome, improving the function of the gastrointestinal barrier, immunomodulatory, an-ti-inflammatory, and antinociceptive properties. According to the literature, these substances not on-ly can improve irritable bowel syndrome symptomatology but also have an excellent long-term safety profile.

Conclusion:Irritable bowel syndrome is a prolonged bowel illness with a lot of gastrointestinal problems. The nutraceuticals treatment works as an anti-IBS intervention and enhances patient compliance with minimum side effects since patients take it better than pharmaceutical treatments.

Об авторах

Ankita Wal

Department of Pharmacy, Pranveer Singh Institute of Technology

Автор, ответственный за переписку.
Email: info@benthamscience.net

Ashish Srivastava

Department of Pharmacy, Pranveer Singh Institute of Technology

Email: info@benthamscience.net

Neha Verma

Department of Pharmacy, Pranveer Singh Institute of Technology

Email: info@benthamscience.net

Shiv Pandey

Department of Pharmacology, Tahira Institute of Medical Sciences, GIDA,

Email: info@benthamscience.net

Sachin Tyagi

Department of Pharmacology, Bharat Institute of Technology, School of Pharmacy Meerut

Email: info@benthamscience.net

Список литературы

  1. Piche T, Ducrotté P, Sabate JM, et al. Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome. Neurogastroenterol Motil 2010; 22(6): 626-e174. doi: 10.1111/j.1365-2982.2010.01502.x PMID: 20403099
  2. Bixquert Jiménez M. Treatment of irritable bowel syndrome with probiotics: An etiopathogenic approach at last? Rev Esp Enferm Dig 2009; 101(8): 553-64. doi: 10.4321/S1130-01082009000800006 PMID: 19785495
  3. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004; 53(5): 666-72. doi: 10.1136/gut.2003.021857 PMID: 15082584
  4. Maratka Z. Abdominal bloating and distension in functional gastrointestinal disorders - epidemiology and possible mechanisms. Aliment Pharmacol Ther 2008; 27(8): 713-4. doi: 10.1111/j.1365-2036.2008.03616.x PMID: 18194494
  5. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26(3): 475-86. doi: 10.1111/j.1365-2036.2007.03362.x PMID: 17635382
  6. Defrees DN, Bailey J. Irritable bowel syndrome: epidemiology, pathophysiology, diagnosis, and treatment. Prim Care 2017; 44(4): 655-71. doi: 10.1016/j.pop.2017.07.009 PMID: 29132527
  7. Brower V. Nutraceuticals: Poised for a healthy slice of the healthcare market? Nat Biotechnol 1998; 16(8): 728-31. doi: 10.1038/nbt0898-728 PMID: 9702769
  8. Das L, Bhaumik E, Raychaudhuri U, Chakraborty R. Role of nutraceuticals in human health. J Food Sci Technol 2012; 49(2): 173-83. doi: 10.1007/s13197-011-0269-4 PMID: 23572839
  9. Kokate CK, Purohit AP, Gokhale SB. Nutraceutical and Cosmaceutical Pharmacognosy. (21st ed.). Pune, India: Nirali Prakashan 2002; pp. 542-9.
  10. Scully P, MacSharry J, O’Mahony D, et al. Bifidobacterium infantis suppression of Peyer’s patch MIP-1α and MIP-1β secretion during Salmonella infection correlates with increased local CD4+CD25+ T cell numbers. Cell Immunol 2013; 281(2): 134-40. doi: 10.1016/j.cellimm.2013.03.008 PMID: 23648818
  11. Joyce SA, MacSharry J, Casey PG, et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci USA 2014; 111(20): 7421-6. doi: 10.1073/pnas.1323599111 PMID: 24799697
  12. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352(9135): 1187-9. doi: 10.1016/S0140-6736(98)02146-1 PMID: 9777836
  13. Ait-Belgnaoui A, Han W, Lamine F, et al. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 2005; 55(8): 1090-4. doi: 10.1136/gut.2005.084194 PMID: 16507583
  14. Kamiya T, Wang L, Forsythe P, et al. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 2006; 55(2): 191-6. doi: 10.1136/gut.2005.070987 PMID: 16361309
  15. Verdú EF, Bercik P, Verma-Gandhu M, et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006; 55(2): 182-90. doi: 10.1136/gut.2005.066100 PMID: 16105890
  16. Eutamene H, Lamine F, Chabo C, et al. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 2007; 137(8): 1901-7. doi: 10.1093/jn/137.8.1901 PMID: 17634262
  17. Talley NJ, Butterfield JH. Mast cell infiltration and degranulation in colonic mucosa in the irritable bowel syndrome. Am J Gastroenterol 1996; 91(8): 1675-6. PMID: 8759703
  18. Scully P, McKernan DP, Keohane J, et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010; 105(10): 2235-43. doi: 10.1038/ajg.2010.159 PMID: 20407431
  19. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EMM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106(2): 329-36. doi: 10.1038/ajg.2010.438 PMID: 21102570
  20. Cammarota G, Ianiro G, Cianci R, Bibbò S, Gasbarrini A, Currò D. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. Pharmacol Ther 2015; 149: 191-212. doi: 10.1016/j.pharmthera.2014.12.006 PMID: 25561343
  21. Roberfroid M, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010; 104 (Suppl. 2): S1-S63. doi: 10.1017/S0007114510003363 PMID: 20920376
  22. Paineau D, Payen F, Panserieu S, et al. The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr 2008; 99(2): 311-8. doi: 10.1017/S000711450779894X PMID: 17697398
  23. Silk DBA, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29(5): 508-18. doi: 10.1111/j.1365-2036.2008.03911.x PMID: 19053980
  24. Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a synbiotic containing Bacillus coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench 2014; 7(3): 156-63. PMID: 25120896
  25. Saneian H, Pourmoghaddas Z, Roohafza H, Gholamrezaei A. Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children. Gastroenterol Hepatol Bed Bench 2015; 8(1): 56-65. PMID: 25584177
  26. Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004; 5(4): 169-74. doi: 10.1111/j.1443-9573.2004.00176.x PMID: 15612887
  27. Eswaran S, Muir J, Chey WD. Fiber and functional gastrointestinal disorders. Am J Gastroenterol 2013; 108(5): 718-27. doi: 10.1038/ajg.2013.63 PMID: 23545709
  28. Chutkan R, Fahey G, Wright WL, McRorie J. Viscous versus nonviscous soluble fiber supplements: Mechanisms and evidence for fiber-specific health benefits. J Am Acad Nurse Pract 2012; 24(8): 476-87. doi: 10.1111/j.1745-7599.2012.00758.x PMID: 22845031
  29. El-Salhy M, Ystad SO, Mazzawi T, Gundersen D. Dietary fiber in irritable bowel syndrome. Int J Mol Med 2017; 40(3): 607-13. doi: 10.3892/ijmm.2017.3072 PMID: 28731144
  30. El-Salhy M. Irritable bowel syndrome: Diagnosis and pathogenesis. World J Gastroenterol 2012; 18(37): 5151-63. doi: 10.3748/wjg.v18.i37.5151 PMID: 23066308
  31. Francis C, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994; 344(8914): 39-40. doi: 10.1016/S0140-6736(94)91055-3 PMID: 7912305
  32. Bijkerk CJ, de Wit NJ, Muris JWM, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009; 339: b3154. doi: 10.1136/bmj.b3154 PMID: 19713235
  33. Soret R, Chevalier J, De Coppet P, et al. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. Gastroenterology 2010; 138(5): 1772-1782.e4. doi: 10.1053/j.gastro.2010.01.053 PMID: 20152836
  34. Gonzalez-Martinez MA, Ortiz-Olvera NX, Mendez-Navarro J. Novel pharmacological therapies for management of chronic constipation. J Clin Gastroenterol 2014; 48(1): 21-8. doi: 10.1097/01.mcg.0000436440.05887.02 PMID: 24172177
  35. Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients 2013; 5(4): 1417-35. doi: 10.3390/nu5041417 PMID: 23609775
  36. Tomlin J, Read NW. Laxative properties of indigestible plastic particles. BMJ 1988; 297(6657): 1175-6. doi: 10.1136/bmj.297.6657.1175 PMID: 2849492
  37. Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. 1993; 7(1): 87-92. doi: 10.1111/j.1365-2036.1993.tb00074.x
  38. Hong SW, Chun J, Park S, Lee HJ, Im JP, Kim JS. Aloe vera is effective and safe in short-term treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Neurogastroenterol Motil 2018; 24(4): 528-35. doi: 10.5056/jnm18077 PMID: 30153721
  39. Hughes PA, Harrington AM, Castro J, et al. Sensory neuro-immune interactions differ between Irritable Bowel Syndrome subtypes. Gut 2013; 62(10): 1456-65. doi: 10.1136/gutjnl-2011-301856 PMID: 22767422
  40. Choghakhori R, Abbasnezhad A, Hasanvand A, Amani R. Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: Association with digestive symptoms and quality of life. Cytokine 2017; 93: 34-43. doi: 10.1016/j.cyto.2017.05.005 PMID: 28506572
  41. López A, de Tangil M, Vega-Orellana O, Ramírez A, Rico M. Phenolic constituents, antioxidant and preliminary antimycoplasmic activities of leaf skin and flowers of Aloe vera (L.) Burm. f. (syn. A. barbadensis Mill.) from the Canary Islands (Spain). Molecules 2013; 18(5): 4942-54. doi: 10.3390/molecules18054942 PMID: 23624648
  42. Davis K, Philpott S, Kumar D, Mendall M. Randomised double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome. Int J Clin Pract 2006; 60(9): 1080-6. doi: 10.1111/j.1742-1241.2006.00980.x PMID: 16749917
  43. Vázquez B, Avila G, Segura D, Escalante B. Antiinflammatory activity of extracts from Aloe vera gel. J Ethnopharmacol 1996; 55(1): 69-75. doi: 10.1016/S0378-8741(96)01476-6 PMID: 9121170
  44. Vaziri ND, Rodríguez-Iturbe B. Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2(10): 582-93. doi: 10.1038/ncpneph0283 PMID: 17003837
  45. Langmead L, Feakins RM, Goldthorpe S, et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004; 19(7): 739-47. doi: 10.1111/j.1365-2036.2004.01902.x PMID: 15043514
  46. Eamlamnam K, Patumraj S, Visedopas N, Thong-Ngam D. Effects of Aloe vera and sucralfate on gastric microcirculatory changes, cytokine levels and gastric ulcer healing in rats. World J Gastroenterol 2006; 12(13): 2034-9. doi: 10.3748/wjg.v12.i13.2034 PMID: 16610053
  47. Werawatganon D, Rakananurak N, Sallapant S, et al. Aloe vera attenuated gastric injury on indomethacin-induced gastropathy in rats. World J Gastroenterol 2014; 20(48): 18330-7. doi: 10.3748/wjg.v20.i48.18330 PMID: 25561799
  48. Ndhlala AR, Amoo SO, Stafford GI, Finnie JF, Van Staden J. Antimicrobial, anti-inflammatory and mutagenic investigation of the South African tree aloe (Aloe barberae). J Ethnopharmacol 2009; 124(3): 404-8. doi: 10.1016/j.jep.2009.05.037 PMID: 19505552
  49. Athiban P, Borthakur B, Ganesan S, Swathika B. Evaluation of antimicrobial efficacy of Aloe vera and its effectiveness in decontaminating gutta percha cones. J Conserv Dent 2012; 15(3): 246-8. doi: 10.4103/0972-0707.97949 PMID: 22876011
  50. Walstab J, Wohlfarth C, Hovius R, et al. Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders. Neurogastroenterol Motil 2014; 26(6): 810-20. doi: 10.1111/nmo.12334 PMID: 24708203
  51. Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther 1988; 2(2): 101-18. doi: 10.1111/j.1365-2036.1988.tb00677.x PMID: 2856502
  52. Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle. Gastroenterology 1991; 101(1): 55-65. doi: 10.1016/0016-5085(91)90459-X PMID: 1646142
  53. Galeotti N, Di Cesare Mannelli L, Mazzanti G, Bartolini A, Ghelardini C. Menthol: a natural analgesic compound. Neurosci Lett 2002; 322(3): 145-8. doi: 10.1016/S0304-3940(01)02527-7 PMID: 11897159
  54. Harries N, James KC, Pugh WK. Antifoaming and carminative actions of volatile oils. J Clin Pharm Ther 1977; 2(3): 171-7. doi: 10.1111/j.1365-2710.1977.tb00087.x
  55. Hawrelak JA, Cattley T, Myers SP. Essential oils in the treatment of intestinal dysbiosis: A preliminary in vitro study. Altern Med Rev 2009; 14(4): 380-4. PMID: 20030464
  56. Juergens UR, Stöber M, Vetter H. The anti-inflammatory activity of L-menthol compared to mint oil in human monocytes in vitro: a novel perspective for its therapeutic use in inflammatory diseases. Eur J Med Res 1998; 3(12): 539-45. PMID: 9889172
  57. Enck P, Junne F, Klosterhalfen S, Zipfel S, Martens U. Therapy options in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2010; 22(12): 1402-11. PMID: 21389791
  58. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil®) in the treatment of irritable bowel syndrome: A prospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007; 39(6): 530-6. doi: 10.1016/j.dld.2007.02.006 PMID: 17420159
  59. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: A prospective, randomized trial. J Gastroenterol 1997; 32(6): 765-8. doi: 10.1007/BF02936952 PMID: 9430014
  60. Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr 2001; 138(1): 125-8. doi: 10.1067/mpd.2001.109606 PMID: 11148527
  61. Ford AC, Talley NJ, Spiegel BMR, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337(nov13 2): a2313. doi: 10.1136/bmj.a2313 PMID: 19008265
  62. Atta AH, Alkofahi A. Anti-nociceptive and anti-inflammatory effects of some Jordanian medicinal plant extracts. J Ethnopharmacol 1998; 60(2): 117-24. doi: 10.1016/S0378-8741(97)00137-2 PMID: 9582001
  63. Ghasemi-Pirbaluti M, Motaghi E, Bozorgi H. The effect of menthol on acute experimental colitis in rats. Eur J Pharmacol 2017; 805: 101-7. doi: 10.1016/j.ejphar.2017.03.003 PMID: 28322843
  64. Perraud A, Knowles HM, Schmitz C. Novel aspects of signaling and ion-homeostasis regulation in immunocytesThe TRPM ion channels and their potential role in modulating the immune response. Mol Immunol 2004; 41(6-7): 657-73. doi: 10.1016/j.molimm.2004.04.013 PMID: 15220002
  65. Ramachandran R, Hyun E, Zhao L, et al. TRPM8 activation attenuates inflammatory responses in mouse models of colitis. Proc Natl Acad Sci USA 2013; 110(18): 7476-81. doi: 10.1073/pnas.1217431110 PMID: 23596210
  66. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 2010; 17(3): 190-7. doi: 10.2174/092986710790149738 PMID: 20214562
  67. Ak T. Gülçin İ. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 2008; 174(1): 27-37. doi: 10.1016/j.cbi.2008.05.003 PMID: 18547552
  68. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009; 41(1): 40-59. doi: 10.1016/j.biocel.2008.06.010 PMID: 18662800
  69. Derosa G, Maffioli P, Simental-Mendía LE, Bo S, Sahebkar A. Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2016; 111: 394-404. doi: 10.1016/j.phrs.2016.07.004 PMID: 27392742
  70. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009; 14(2): 141-53. PMID: 19594223
  71. Lubbad A, Oriowo MA, Khan I. Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 2009; 322(1-2): 127-35. doi: 10.1007/s11010-008-9949-4 PMID: 19002562
  72. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005; 50(11): 2191-3. doi: 10.1007/s10620-005-3032-8 PMID: 16240238
  73. Yu Y, Wu S, Li J, et al. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. Metab Brain Dis 2015; 30(1): 47-55. doi: 10.1007/s11011-014-9554-z PMID: 24807589
  74. Lü JM, Lin PH, Yao Q, Chen C. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. J Cell Mol Med 2010; 14(4): 840-60. doi: 10.1111/j.1582-4934.2009.00897.x PMID: 19754673
  75. Walker AF, Middleton RW, Petrowicz O. Artichoke leaf extract reduces symptoms of irritable bowel syndrome in a post-marketing surveillance study. Phytother Res 2001; 15(1): 58-61. doi: 10.1002/1099-1573(200102)15:13.0.CO;2-R PMID: 11180525
  76. Costabile A, Kolida S, Klinder A, et al. A double-blind, placebo-controlled, cross-over study to establish the bifidogenic effect of a very-long-chain inulin extracted from globe artichoke (Cynara scolymus) in healthy human subjects. Br J Nutr 2010; 104(7): 1007-17. doi: 10.1017/S0007114510001571 PMID: 20591206
  77. Emendörfer F, Emendörfer F, Bellato F, et al. Antispasmodic activity of fractions and cynaropicrin from Cynara scolymus on guinea-pig ileum. Biol Pharm Bull 2005; 28(5): 902-4. doi: 10.1248/bpb.28.902 PMID: 15863902
  78. Currò D, Ianiro G, Pecere S, Bibbò S, Cammarota G. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol 2017; 174(11): 1426-49. doi: 10.1111/bph.13632 PMID: 27696378
  79. Mehmood MH, Munir S, Khalid UA, Asrar M, Gilani AH. Antidiarrhoeal, antisecretory and antispasmodic activities of Matricaria chamomilla are mediated predominantly through K+-channels activation. BMC Complement Altern Med 2015; 15(1): 75. doi: 10.1186/s12906-015-0595-6 PMID: 25886126
  80. Mahboubi M. Caraway as important medicinal plants in management of diseases. Nat Prod Bioprospect 2019; 9(1): 1-11. doi: 10.1007/s13659-018-0190-x PMID: 30374904
  81. Abascal K, Yarnell E. Combining herbs in a formula for irritable bowel syndrome. Altern Complement Ther 2005; 11(1): 17-23. doi: 10.1089/act.2005.11.17
  82. Dolatabadi F, Abdolghaffari AH, Farzaei MH, et al. The protective effect of Melissa officinalis L. in visceral hypersensitivity in rat using 2 models of acid-induced colitis and stress-induced irritable bowel syndrome: a possible role of nitric oxide pathway. J Neurogastroenterol Motil 2018; 24(3): 490-501. doi: 10.5056/jnm17035 PMID: 29879761
  83. Zielińska S, Jezierska-Domaradzka A, Wójciak-Kosior M, Sowa I, Junka A, Matkowski AM. Greater Celandine’s ups and downs-21 centuries of medicinal uses of Chelidonium majus From the Viewpoint of Today’s Pharmacology. Front Pharmacol 2018; 9: 299. doi: 10.3389/fphar.2018.00299 PMID: 29713277
  84. Das SK, Mukherjee S, Vasudevan DM. Medicinal properties of milk thistle with special reference to silymarin–an overview. Nat Prod Radiance 2008; 7(2): 182-92.
  85. Załęski A, Banaszkiewicz A, Walkowiak J. Butyric acid in irritable bowel syndrome. Prz Gastroenterol 2013; 6(6): 350-3. doi: 10.5114/pg.2013.39917 PMID: 24868283
  86. Kim MH, Kim H. The roles of glutamine in the intestine and its implication in intestinal diseases. Int J Mol Sci 2017; 18(5): 1051. doi: 10.3390/ijms18051051 PMID: 28498331
  87. Zhou Q, Souba WW, Croce CM, Verne GN. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut 2010; 59(6): 775-84. doi: 10.1136/gut.2009.181834 PMID: 19951903
  88. Rastgoo S, Ebrahimi-Daryani N, Agah S, et al. Glutamine Supplementation Enhances the Effects of a Low FODMAP Diet in Irritable Bowel Syndrome Management. Front Nutr 2021; 8: 746703. doi: 10.3389/fnut.2021.746703 PMID: 34977110
  89. Chong RIH, Yaow CYL, Loh CYL, et al. Vitamin D supplementation for irritable bowel syndrome: A systematic review and meta‐analysis. J Gastroenterol Hepatol 2022; 37(6): 993-1003. doi: 10.1111/jgh.15852 PMID: 35396764
  90. Filgueiras MS, Rocha NP, Novaes JF, Bressan J. Vitamin D status, oxidative stress, and inflammation in children and adolescents: A systematic review. Crit Rev Food Sci Nutr 2020; 60(4): 660-9. doi: 10.1080/10408398.2018.1546671 PMID: 30596263
  91. Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol 2016; 1(2): 133-46. doi: 10.1016/S2468-1253(16)30023-1 PMID: 28404070

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Bentham Science Publishers, 2024